Pari CR 37.5 is a generic controlled-release paroxetine tablet designed to provide sustained delivery of the active ingredient throughout the day, optimizing therapeutic effects while minimizing peak-related side effects. As a selective serotonin reuptake inhibitor (SSRI), it enhances serotonin signaling, which plays a pivotal role in mood stabilization, anxiety reduction, and overall emotional well-being.

- Sleep & Mental Health > Depression, Anxiety, PTSD This medication effectively treats major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, and post-traumatic stress disorder (PTSD). It promotes emotional stability and modulates stress responses for comprehensive mental health support. > Obsessive-Compulsive Disorder (OCD) Pari CR 37.5 is FDA-approved for OCD treatment, helping reduce persistent obsessive thoughts and compulsive behaviors by balancing serotonin levels. > Panic Disorder It plays a critical role in managing panic disorder by reducing the frequency and severity of panic attacks and preventing relapses.

Paroxetine works by selectively inhibiting the serotonin transporter, increasing the availability of serotonin in the synaptic cleft. This mechanism improves communication between neurons, alleviating symptoms of depression, anxiety, and related psychiatric conditions.

Adult Dosing - Depression & Major Depressive Disorder (MDD): Immediate Release (IR): Start 20 mg daily; maintenance dose ranges from 20 to 50 mg, with a maximum of 50 mg. Controlled Release (CR): Start 25 mg daily; maintenance dose ranges from 25 to 62.5 mg, with a maximum of 62.5 mg. Dose increments typically occur weekly by 10 mg (IR) or 12.5 mg (CR). Treatment duration usually spans several months, with efficacy documented up to one year. - Social Anxiety Disorder (SAD): IR: Start 20 mg daily; maintenance dose 20 to 60 mg, max 60 mg. CR: Start 12.5 mg daily; maintenance dose 12.5 to 37.5 mg, max 37.5 mg. Treatment generally continues up to 12 weeks with weekly dose escalation. - Panic Disorder (PD): IR: Start 10 mg daily; maintenance dose 10 to 40 mg, max 60 mg. CR: Start 12.5 mg daily; maintenance dose 12.5 to 75 mg, max 75 mg. Treatment is commonly up to 12 weeks, with dose adjustments weekly. - Premenstrual Dysphoric Disorder (PMDD): CR only; dosing ranges from 12.5 to 25 mg daily, administered either continuously or cyclically. Recommended treatment lasts for at least 3 menstrual cycles, with potential dose increases weekly. - Obsessive Compulsive Disorder (OCD): IR: Start 20 mg daily; maintenance dose 20 to 60 mg, max 60 mg. Requires long-term treatment with weekly dose increases of 10 mg. - Post-Traumatic Stress Disorder (PTSD) & Generalized Anxiety Disorder (GAD): IR: Start 20 mg daily; maintenance dose 20 to 50 mg, max 50 mg. Treatment duration up to 12 weeks with weekly dose titration. - Postmenopausal Symptoms: Mesylate capsules dosed at 7.5 mg daily, specifically for vasomotor symptom relief. Geriatric Dosing: - Initiate therapy at lower doses (approximately 10 mg daily), with maintenance doses up to 40 mg/day for OCD, PTSD, SAD, GAD, PD, and depression. - Weekly dose increases are recommended, considering heightened sensitivity in elderly patients. - Not recommended for mild, short-term anxiety related to everyday stressors.

Store Pari CR 37.5 tablets in a sealed container, placed in a cool, dry, and dark environment away from moisture and direct sunlight. Protect from heat and humidity to maintain stability. Keep the medication out of reach of children and pets to prevent accidental ingestion.

Common adverse effects include nausea, headache, dizziness, insomnia, dry mouth, excessive sweating, fatigue, and sexual dysfunction. More serious risks include serotonin syndrome, bleeding disorders, and withdrawal symptoms if abruptly discontinued. Continuous monitoring is essential, and dose adjustments should be based on patient tolerance and response.